^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1)

    i
    Other names: BRCA1 Interacting Protein C-Terminal Helicase 1, BRCA1-Associated C-Terminal Helicase 1, BRCA1/BRCA2-Associated Helicase 1, ATP-Dependent RNA Helicase BRIP1, Fanconi Anemia Group J Protein, BACH1, FANCJ, BRCA1-Binding Helicase-Like Protein BACH1, BRCA1-Interacting Protein 1, Protein FACJ, BRCA1 Interacting Protein C-terminal Helicase 1
    1d
    Metabolic Responses of Three Distinct Melanoma Cell Lines to UVA Radiation and Cannabigerol. (PubMed, Free Radic Biol Med)
    Moreover, increased proapoptotic signaling (SK-MEL-1) was clearly observed, with increased expression of caspase-3 (UVA) and caspase-8 (CBG or UVA). Thus, CBG does not explicitly promote apoptosis but influences it by regulating oxidative and inflammatory processes in a cell-type-dependent manner.
    Preclinical • Journal
    |
    KEAP1 (Kelch Like ECH Associated Protein 1) • TNFA (Tumor Necrosis Factor-Alpha) • BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1) • CASP3 (Caspase 3) • CASP8 (Caspase 8) • BACH1 (BTB Domain And CNC Homolog 1) • NLRP3 (NLR Family Pyrin Domain Containing 3)
    7d
    Cannabigerol Reduces Lipid Peroxidation Influencing Oxidative Stress and Inflammation Signaling Pathways in Melanocytes Exposed to UVA Radiation. (PubMed, Front Biosci (Landmark Ed))
    These results suggest that CBG may protect melanocytes from UVA-induced oxidative changes and lipid peroxidation by activating the Nrf2-dependent antioxidant system and inhibiting NFκB-based pro-inflammatory signaling. CBG can therefore create favorable conditions for the physiological functioning of melanocytes after UVA exposure, ultimately reducing the risk of inflammatory skin responses and neoplastic transformation.
    Journal
    |
    KEAP1 (Kelch Like ECH Associated Protein 1) • BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1) • BACH1 (BTB Domain And CNC Homolog 1)
    7d
    Enhancement of Rotenone Cytotoxicity in the Presence of Bach1 Inhibitors. (PubMed, Dokl Biochem Biophys)
    According to the PCR results, HT-29 was the only line showing an extremely high activation of heme oxygenase 1 (HMOX1) in the presence of the Bach1 inhibitor, pointing to the highest level of the antioxidant defense in this cell line. The sensitivity of the prostate cancer cell lines to the combination therapy points to the significant differences in the metabolism between the prostate and colorectal cell lines.
    Journal
    |
    BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1) • HMOX1 (Heme Oxygenase 1) • BACH1 (BTB Domain And CNC Homolog 1)
    7d
    Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial (clinicaltrials.gov)
    P2, N=88, Recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2026 --> Dec 2027
    Trial completion date
    |
    KRAS (KRAS proto-oncogene GTPase) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • RAD51 (RAD51 Homolog A) • FANCA (FA Complementation Group A) • BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1) • RAD51C (RAD51 paralog C) • RAD51D (RAD51 paralog D) • BARD1 (BRCA1 Associated RING Domain 1)
    |
    KRAS mutation • BRCA2 mutation • BRCA1 mutation • KRAS G12C • KRAS G12 • BRIP1 mutation • RAD51C mutation • RAD51D mutation • BARD1 mutation
    |
    Talzenna (talazoparib) • ZEN-3694
    11d
    PROTECT-C: Population Based Germline Testing for Early Detection and Prevention of Cancer (clinicaltrials.gov)
    P=N/A, N=6000, Recruiting, Queen Mary University of London
    New trial
    |
    BRCA2 (Breast cancer 2, early onset) • PALB2 (Partner and localizer of BRCA2) • BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1)
    14d
    A Rare Case of Adenoid Cystic Breast Cancer: A Case Report and Literature Review. (PubMed, Case Rep Oncol)
    Breast AdCC, though rare, requires heightened clinical awareness for accurate diagnosis and management. This case underscores the potential role of genetic evaluation in rare breast cancer subtypes and the importance of continued case reporting to guide future recommendations.
    Journal
    |
    BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1)
    14d
    A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors (clinicaltrials.gov)
    P1/2, N=120, Recruiting, National Cancer Institute (NCI) | Trial completion date: Mar 2027 --> Mar 2029 | Trial primary completion date: Mar 2026 --> Mar 2028
    Trial completion date • Trial primary completion date
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • HRD (Homologous Recombination Deficiency) • CDK12 (Cyclin dependent kinase 12) • BRCA (Breast cancer early onset) • CHEK2 (Checkpoint kinase 2) • RAD51B (RAD51 Paralog B) • BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1) • RAD51C (RAD51 paralog C) • RAD51D (RAD51 paralog D) • CHEK1 (Checkpoint kinase 1) • BARD1 (BRCA1 Associated RING Domain 1) • RAD54L (DNA Repair And Recombination Protein RAD54) • FANCL (FA Complementation Group L) • PPP2R2A (Protein Phosphatase 2, Regulatory Subunit B, Alpha)
    |
    BRCA1 mutation • ATM mutation • PALB2 mutation • CDK12 mutation • CHEK2 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation • CHEK1 mutation • RAD54L mutation
    |
    berzosertib (M6620) • Trodelvy (sacituzumab govitecan-hziy)
    25d
    Role and Mechanism of BRIP1 in Anoikis Resistance of Gastric Cancer. (PubMed, Int J Mol Sci)
    We found that the PI3K inhibitor LY294002 counteracted BRIP1-driven oncogenic effects, which was evidenced by restored expression of key regulators governing apoptosis, cell cycle progression, and EMT, in addition to suppressed proliferation in GC cells. BRIP1 is postulated to function upstream of the PI3K/Akt signaling cascade. This study establishes a risk scoring model and identifies BRIP1 as a potential prognostic marker for GC.
    Journal
    |
    BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1) • TXNIP (Thioredoxin Interacting Protein) • DUSP1 (Dual Specificity Phosphatase 1)
    |
    LY294002
    30d
    Integrating breast tumour homologous recombination deficiency status to aid germline BRCA1 and BRCA2 variant classification. (PubMed, EBioMedicine)
    Analysis across multiple tumour whole-genome sequencing datasets has shown that HR status prediction algorithms can separate profiles for BRCA1 and BRCA2 pathogenic variants and provide further evidence at increased weight to aid in the classification of germline BRCA1 and BRCA2 variants. Tumour sequencing offers a promising strategy for reducing the uncertainty in germline variant interpretation.
    Journal • BRCA Biomarker
    |
    TP53 (Tumor protein P53) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • PTEN (Phosphatase and tensin homolog) • ATM (ATM serine/threonine kinase) • HRD (Homologous Recombination Deficiency) • PALB2 (Partner and localizer of BRCA2) • BRCA (Breast cancer early onset) • CHEK2 (Checkpoint kinase 2) • BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1) • RAD51C (RAD51 paralog C) • RAD51D (RAD51 paralog D) • BARD1 (BRCA1 Associated RING Domain 1)
    |
    HRD
    1m
    Identification of Genetic Variants Among Breast Cancer Patients and At-Risk Individuals: A Cohort Study in Sri Lanka. (PubMed, Breast Cancer (Auckl))
    Three pathogenic variants, BRCA2 [c.6509A>G; c.7879A>T; c.5574_5577delAATT] and PALB2 [c.1592delT], were identified in high-risk genes important for breast cancer prediction. Identification of population-based variants may improve breast cancer screening and management in Sri Lanka.
    Journal • BRCA Biomarker
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • NF1 (Neurofibromin 1) • PALB2 (Partner and localizer of BRCA2) • BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1) • MRE11A (MRE11 homolog, double strand break repair nuclease) • MUTYH (MutY homolog)
    |
    BRCA2 mutation • PALB2 mutation
    1m
    BRIP1-Mediated RINT1 Acetylation and NF-κB Activation Promote DNA Repair and Immunosuppressive Microenvironment in Lung Adenocarcinoma. (PubMed, Cancer Lett)
    In vivo, BRIP1 overexpression accelerates tumor growth and metastasis while conferring resistance to PD-L1 blockade, which is effectively reversed by combining anti-PD-L1 therapy with STING activation. Collectively, our findings establish BRIP1 as a molecular link between DNA repair proficiency and immune suppression in LUAD, highlighting BRIP1-associated pathways as actionable targets for rational combination immunotherapy.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1) • RAD50 (RAD50 Double Strand Break Repair Protein) • STING (stimulator of interferon response cGAMP interactor 1) • ALKBH5 (AlkB Homolog 5, RNA Demethylase)
    2ms
    SPORE: A Study of Pembrolizumab and Olaparib for People With Metastatic Pancreatic Ductal Adenocarcinoma and Homologous Recombination Deficiency or Exceptional Treatment Response to Platinum-Based Therapy (clinicaltrials.gov)
    P2, N=63, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Jan 2026 --> Jan 2027 | Trial primary completion date: Jan 2026 --> Jan 2027
    Trial completion date • Trial primary completion date
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • ATM (ATM serine/threonine kinase) • BAP1 (BRCA1 Associated Protein 1) • CHEK2 (Checkpoint kinase 2) • RAD51 (RAD51 Homolog A) • FANCA (FA Complementation Group A) • BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1) • RAD51C (RAD51 paralog C) • RAD50 (RAD50 Double Strand Break Repair Protein) • BARD1 (BRCA1 Associated RING Domain 1) • NBN (Nibrin Nijmegen Breakage Syndrome 1 (Nibrin)) • ABRAXAS1 (Abraxas 1 BRCA1 A Complex Subunit 2) • FANCC (FA Complementation Group C)
    |
    MSK-IMPACT
    |
    Keytruda (pembrolizumab) • Lynparza (olaparib)